| Reagan-Udall Foundation

Read more about Rehabilitation of Fatigue in Patients with Post-COVID-19 Syndrome

Read more about Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months

Read more about A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses

Read more about A Comparison Between The Efficacy of Modified Thoracoabdominal Plane Block Via Perichondral Approach (M-TAPA) And External Oblique Intercostal Plane Block (EOIPB) in Patients Undergoing Laparoscopic Cholecystectomy Surgeries (LC)

Read more about EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Read more about Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients

On the FDA’s behalf, the Reagan-Udall Foundation has held roundtables with industry members to share insights, identify and prioritize key issues, and explore implementation strategies.

Coverage

Read more about Institute of Food Technologists: Countdown to Compliance

Read more about "Artificial Intelligence-Based Data Analysis Results and Mortality Prediction in Covid-19 Patients in Intensive Care"

Read more about Treatment Protocol of Plozasiran in Adults With FCS

Read more about A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)

Subscribe to

(202) 849 - 2075

1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036

admin@reaganudall.org

Subscribe for updates from the Reagan-Udall Foundation for the FDA